In the analysis of 10 trials with SGLT-2 inhibitors (Fig. 7, Table 2), the risk of hospitalization for HF was reduced by 32% (HR = 0.68, 95% CI 0.62–0.74), with no heterogeneity (I2 = 0%) and no evidence of publication bias (Egger test, P = 0.85). Here, SLC5A2 is linked to hydrops fetalis.